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Brief Communications
Inhibition of Group I Metabotropic Glutamate Receptors
Reverses Autistic-Like Phenotypes Caused by Deficiency of
the Translation Repressor eIF4E Binding Protein 2
Argel Aguilar-Valles,1,2 EdnaMatta-Camacho,2 XArkady Khoutorsky,2 XChristos Gkogkas,2,4 Karim Nader,3
X Jean-Claude Lacaille,1* and Nahum Sonenberg2*
1Department of Neurosciences and Groupe de Recherche sur le Syste`me Nerveux Central, Universite´ de Montre´al, Montre´al, Que´bec H3C 3J7, Canada,
2Department of Biochemistry and Goodman Cancer Centre, McGill University, Montre´al, Que´bec H3A 1A3, Canada, 3Department of Psychology, McGill
University, Montre´al, Que´bec H3A 1B1, Canada, and 4Patrick Wild Centre and Centre for Integrative Physiology, University of Edinburgh, Edinburgh EH8
9XD, United Kingdom
ExacerbatedmRNA translation during brain development has been linked to autism spectrumdisorders (ASDs). Deletion of the eukary-
otic initiation factor 4E (eIF4E)-binding protein 2 gene (Eif4ebp2), encoding the suppressor ofmRNA translation initiation 4E-BP2, leads
to an imbalance in excitatory-to-inhibitory neurotransmission and ASD-like behaviors. Inhibition of group I metabotropic glutamate
receptors (mGluRs) mGluR1 and mGluR5 reverses the autistic phenotypes in several ASD mouse models. Importantly, these receptors
control synaptic physiology via activation of mRNA translation. We investigated the potential reversal of autistic-like phenotypes in
Eif4ebp2 / mice by using antagonists of mGluR1 (JNJ16259685) or mGluR5 (fenobam). Augmented hippocampal mGluR-induced
long-term depression (LTD; or chemically induced mGluR-LTD) in Eif4ebp2 /mice was rescued by mGluR1 or mGluR5 antagonists.
While rescue bymGluR5 inhibition occurs through the blockade of a protein synthesis-dependent component of LTD, normalization by
mGluR1 antagonists requires the activation of protein synthesis. Synaptically induced LTD was deficient in Eif4ebp2 /mice, and this
deficit was not rescued by group I mGluR antagonists. Furthermore, a single dose of mGluR1 (0.3 mg/kg) or mGluR5 (3 mg/kg) antago-
nists in vivo reversed the deficits in social interaction and repetitive behaviors (marble burying) in Eif4ebp2 / mice. Our results
demonstrate that Eif4ebp2 / mice serve as a relevant model to test potential therapies for ASD symptoms. In addition, we provide
substantive evidence that the inhibition ofmGluR1/mGluR5 is an effective treatment for physiological and behavioral alterations caused
by exacerbated mRNA translation initiation.
Key words: autism spectrum disorders; group I mGluRs; long-term depression; repetitive behavior; social interaction; translation
initiation
Introduction
Autism spectrum disorders (ASDs) are thought to be caused by
an imbalance in the ratio of excitatory-to-inhibitory (E/I) neu-
rotransmission due to impaired neurodevelopment (Kelleher
and Bear, 2008). Several single-gene disorders, harboring muta-
tions upstream of the mammalian target of rapamycin (mTOR)
complex 1 (mTORC1), manifest high rates of autism and are
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Exacerbated mRNA translation during brain development is associated with several autism spectrum disorders (ASDs). We recently
demonstratedthat thedeletionofanegativeregulatorofmRNAtranslation initiation, theeukaryotic initiationfactor4E-bindingprotein
2, leads toASD-likebehaviorsand increasedexcitatorysynapticactivity.Herewedemonstrated thatautisticbehavioral andelectrophys-
iological phenotypes can be treated in adult mice with antagonists of group Imetabotropic glutamate receptors (mGluRs), which have
been previously used in other ASDmodels (i.e., fragile X syndrome). These findings support the use of group ImGluR antagonists as a
potential therapy that extends to autismmodels involving exacerbatedmRNA translation initiation.
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characterized by increased cap-dependent mRNA translation of
synaptic proteins (Kelleher and Bear, 2008). These disorders in-
clude tuberous sclerosis complex (Curatolo et al., 2010) and
PTEN (phosphatase and tensin homolog) hamartoma tumor
syndrome (Butler et al., 2005).
mTORC1 activates cap-dependent translation via phosphor-
ylation and inactivation of the eukaryotic initiation factor 4E
(eIF4E) binding proteins (4E-BPs; Gingras et al., 1999). eIF4E is
the cap-binding component of the eIF4F complex, which also
contains the RNA helicase, eIF4A, and the modular scaffolding
protein eIF4G, which bridges themRNA to the ribosome. 4E-BPs
repress translation initiation by binding to eIF4E and preventing
the eIF4E–eIF4G interaction, thereby inhibiting eIF4F complex
formation. There are three 4E-BP isoforms, of which 4E-BP2 is
the predominant form in the brain (Tsukiyama-Kohara et al.,
2001; Banko et al., 2005).
Recently, we (Gkogkas et al., 2013) and Santini et al. (2013)
demonstrated that excessive eIF4E activity promotes the devel-
opment of ASD-like behaviors in mice. Genetic deletion of
Eif4ebp2 (encoding 4E-BP2) or overexpression of Eif4e resulted
in augmented translation of mRNAs encoding for neuroligins,
engendering an imbalance in the E/I ratio, impaired social inter-
action, repetitive behaviors, and vocalization defects (Gkogkas et
al., 2013; Santini et al., 2013).
Group I metabotropic glutamate receptors (mGluRs), com-
prising mGluR1 and mGluR5, have been explored as a therapeu-
tic target for fragile X syndrome (FXS; Bear et al., 2004) and other
disorders with autistic features (Tian et al., 2015). FXS is a genetic
disorderwith a high prevalence of autism caused by the loss of the
negative regulator of mRNA translation FMR1 (Weiler et al.,
1997). In Fmr1-null mice, mGluR1/mGluR5 activation induces
exacerbated hippocampal long-term depression (mGluR-LTD;
Huber et al., 2002; Hou et al., 2006; Nosyreva and Huber, 2006).
mGluR-LTD is dependent on de novo protein synthesis (Weiler
and Greenough, 1993; Huber et al., 2000), and involves the acti-
vation of mTORC1 and cap-dependent translation (Hou and
Klann, 2004; Banko et al., 2006; Antion et al., 2008). Importantly,
mGluR-dependent LTD is also exacerbated in Eif4ebp2-null mice
(Banko et al., 2006); thus, inhibition of group I mGluRs could
benefit ASD caused by dysregulated cap-dependent translation
initiation.We sought to determine whether mice lacking 4E-BP2
could serve as a useful model to investigate therapies aimed to
improve decreased social interaction and repetitive behaviors.
Consequently, we determined whether mGluR1 or mGluR5 an-
tagonists could rescue the synaptic and behavioral deficits in
Eif4ebp2 knock-out mice.
Materials andMethods
Eif4ebp2 knock-out mice were previously described (Banko et al., 2005).
Male littermates from heterozygote crossings were housed in temp-
erature-controlled (21°C) and humidity-controlled (55%) rooms,
with ad libitum food and water, and a 12 h light/dark cycle. All proce-
dures were conducted in compliance with the Canadian Council on An-
imal Care guidelines and were approved by the McGill University and
Universite´ de Montre´al Animal Care Committees.
Electrophysiology. Transverse hippocampal slices (400 m thickness),
prepared from 30- to 35-d-old male mice, were allowed to recover for at
least 2 h at 32°C submerged in oxygenated artificial CSF (ACSF; 124 mM
NaCl, 5 mM KCl, 1.25 mM NaH2PO4, 2 mM MgSO4, 2 mM CaCl2, 26 mM
NaHCO3, and 10 mM glucose) and were perfused with ACSF for an
additional 30 min in a recording chamber at 27–28°C. Field EPSPs
(fEPSPs) were recorded in CA1 stratum radiatum with glass electrodes
(2–3 M) filled with ASCF. Schaffer collateral fEPSPs were evoked with
a concentric bipolar tungsten stimulating electrode placed in mid-
stratum radiatum proximal to the CA3 region. Baseline stimulation was
applied at 0.033Hz by delivering 0.1ms pulses, with intensity adjusted to
evoke fEPSPs with 60% of maximal amplitude. For chemically induced
mGluR-LTD, CA1 and CA3 hippocampal regions were isolated by a
surgical cut before recovery, and group I mGluR agonist (S)-3,5-
dihydroxyphenylglycine (DHPG; 50M; Tocris Bioscience)was added to
ACSF for 10 min for induction. For synaptically induced LTD, paired-
pulse low-frequency stimulation (PP-LFS) was performed as reported
(Huber et al., 2000; Volk et al., 2006). PP-LFS stimulation (50 ms inter-
stimulus interval) was administered at 1 Hz for 20min in the presence of
the NMDAR antagonist aminophosphonovalerate (50 M). fEPSP slope
measurements were performed on digitized analog recordings using the
Clampfit analyze function. The slope was measured at between 10% and
90% of maximal fEPSP amplitude during an epoch defined by constant
cursor placements, which excluded fiber volley and population spikes.
Where indicated, we used anisomycin (40M; Tocris Bioscience) 20min
prior to, during, and for 20 min after LTD induction; and fenobam,
an mGluR5 antagonist (0.9 M; Tocris Bioscience), or JNJ16259685, an
mGluR1 antagonist (6 nM; Tocris Bioscience) 10 min prior to, during,
and for 5 min after LTD induction.
In vivo experiments. To assess the concentration of fenobam or
JNJ16259685 that had no effect on the social behavior of wild-type mice,
7-week-old wild-type C57BL/6J mice were treated with vehicle [30%
DMSO in 0.9%NaCl; 8ml/kg bodyweight (BW), i.p.], JNJ16259685 (0.3
or 1mg/kg BW), or fenobam (3 or 10mg/kg BW) and tested 30min later.
After determining the concentrations that spared social behavior inwild-
type mice, a different cohort of wild-type and Eif4ebp2 / mice was
treated with the chosen doses of each antagonist (0.3 mg/kg for
JNJ16259685; 3 mg/kg for fenobam) or vehicle, and 30min or 24 h after,
brains were collected, hippocampi were isolated, flash frozen, and used
later for Western blotting.
In separate experiments, Eif4ebp2 /mice and wild-type littermates
were treated with vehicle and tested for social interaction 30 min after
injection. One week after, mice were treated with either JNJ16259685 or
fenobam and tested again for social interaction 30 min after injection.
Twenty-four hours after treatment, mice were tested again without fur-
ther injections. The social behavior of wild-type mice treated with
JNJ16259285 or fenobam was indistinguishable, and data from both
groups were pooled. For the marble-burying test, a different cohort of
micewas treatedwith vehicle, JNJ16259685, and fenobam, and examined
in the marble-burying test 30 min after injection. In all cases, the quan-
tification of behavior was performed on recorded video by an experi-
menter who was blind to genotype and treatment.
Social preference test. A three-chamber arena was used to assess social
approach, as previously reported (Gkogkas et al., 2013), except that ha-
bituation and social preference sessions lasted 10 min.
Marble-burying task. Mice were individually placed in Plexiglas cages
containing 5-cm-deep fresh bedding with 20 black marbles prearranged
in 5  4 evenly spaced rows for 20 min (Gkogkas et al., 2013). Marbles
were considered to be buried if at least one-half was covered with
bedding.
Western blotting and antibodies.Tissueswere dissociated inRIPAbuffer.
Western blotting was performed as previously described (Bidinosti et al.,
2010). The antibodies used against indicated proteins were as follows:
phospho-S6 ribosomal protein (pS6; Ser235/236, 1:1000; Cell Signaling
Technology); total S6 ribosomal protein (tS6; 1:1000; Cell Signaling Tech-
nology); and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), cou-
pled to horseradish peroxidase (1:5000; Abcam). The secondary antibodies
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used were anti-mouse and anti-rabbit (GE Healthcare). Quantification of
immunoblots was performed using ImageJ (National Institutes of Health).
Values were normalized to GAPDH and expressed as a ratio of
pS6/tS6/GAPDH.
Statistical analysis. All data are presented as the mean SEM. Electro-
physiology, Western blotting, and marble-burying test data were analyzed
using a two-way ANOVA (using genotype and treatment as between-
subjects factors), except for mGluR-LTD data from Eif4ebp2 / treated
with both anisomycin and JNJ16259285 or fenobam,whichwere compared
only to Eif4ebp2 / treated with JNJ16259285 or fenobam using a two-
tailed Student’s t test. Social preference data in wild-typemice (see Fig. 3)
were analyzed using repeated-measures ANOVA (using time in cham-
bers as the within-subject factor) independently for each treatment. So-
cial preference data (see Fig. 4) were analyzed using two-way ANOVA,
with treatment used as the between-subjects factor and with chamber
used as the within-subject factor; each time point (baseline, 0.5, and 24 h
after treatment) were analyzed independently as no comparisons be-
tween these were intended. When the main factor or interaction of an
ANOVA was significant, analysis was followed by Bonferroni-corrected
pairwise comparisons. p values0.05 were deemed significant.
Results
Exacerbated group I mGluR-dependent LTD is rescued by
inhibition of mGluR1/mGluR5
We first tested the effect of mGluR1 or mGluR5 antagonists on ex-
acerbated mGluR-LTD in Eif4ebp2 / mice. As previously re-
ported (Banko et al., 2006), DHPG-induced LTD in the CA1 region
of the hippocampus was significantly exacerbated in Eif4ebp2 /
mice (Eif4ebp2/ vs Eif4ebp2 / vehicle; F(1,119) 	 10.01, p 	
0.002; Fig. 1A,E). In wild-typemice, hippocampalmGluR-LTD in-
duction is dependent on the activation of both mGluR1 and
mGluR5, andpharmacological inhibitionof onlyoneof these recep-
tors during induction is not sufficient to block mGluR-LTD (Hou
and Klann, 2004; Volk et al., 2006). Accordingly, incubation wi-
th either JNJ16259685 (mGluR1) or fenobam (mGluR5) in
Eif4ebp2/mice did not affect mGluR-LTD (F(3,119)	 5.31, p	
0.002, vehicle vs JNJ16259685 or fenobam, p	 1.0; Fig. 1B,C,E). In
contrast, in Eif4ebp2 /mice, JNJ16259685 and fenobam reduced
mGluR-LTD (F(3,119) 	 9.46, p	 0.0009; vehicle vs JNJ16259685,
p	 0.00109; vehicle vs fenobam, p	 0.001; Fig. 1B,C,E) to control
levels for JNJ16259685 or to a greater degree than control levels for
fenobam. These results demonstrate a greater sensitivity of hip-
pocampal mGluR-LTD in Eif4ebp2 / mice to the inhibition of
either mGluR1 or mGluR5, which results in the rescue of synaptic
plasticity deficits caused by increased cap-dependent translation
initiation.
Todetermine the relationship between the rescuedmGluR-LTD in
Eif4ebp2 /miceandprotein synthesis,we treatedhippocampal slices
with the protein synthesis inhibitor anisomycin, alone or in combina-
tionwitheither JNJ16259685or fenobam(Fig.1B–E).Asexpected, ani-
somycin completely inhibited hippocampal mGluR-LTD in wild-type
mice (Eif4ebp2/ vehicle vs anisomycin, p	 0.002; Fig. 1D,E), while
Figure 1. Enhanced LTD in Eif4ebp2 /mice is normalized bymGluR1 andmGluR5 antagonists. A, DHPG induced enhanced LTD in Eif4ebp2 /mice comparedwith Eif4ebp2/mice.B,
ThemGluR1 antagonist JNJ16259285 abrogated the difference in LTD between Eif4ebp2/ and Eif4ebp2 /without affectingwild-typemice . This effectwas preventedwhen anisomycinwas
coadministered. C, Fenobam, an mGluR5 antagonist, also normalized mGluR-LTD in Eif4ebp2 /mice without affecting Eif4ebp2/mice. Anisomycin cotreatment did not further affect the
normalizedmGluR-LTD.D, In thepresenceof anisomycin,mGluR-LTDwas completely blocked inwild-typemice, but onlynormalized in4E-BP2mutantmice.E, fEPSP slopeat 50–60minafterDHPG
application for Eif4ebp2/ (n	 23), Eif4ebp2/ plus JNJ16259285 (n	 12), Eif4ebp2/ plus fenobam (n	 11), Eif4ebp2/ plus anisomycin (n	 12), Eif4ebp2 / (n	 33),
Eif4ebp2 / plus JNJ16259285 (n	 15), Eif4ebp2 / plus fenobam (n	 11), Eif4ebp2 / plus anisomycin (n	 12), Eif4ebp2 / plus JNJ16259285 and anisomycin (n	 10), and
Eif4ebp2 / plus fenobam and anisomycin (n	 8). Insets inA–D are representative traces. Calibration: 50ms and 0.5mV. **p 0.01 vs Eif4ebp2/ plus vehicle; $p 0.05 vs Eif4ebp2/
plus fenobam; #p 0.05, ##p 0.01, and ###p 0.001 vs Eif4ebp2 / plus vehicle; &&&p 0.001 vs Eif4ebp2 / plus JNJ16259285; N.S. vs Eif4ebp2 / plus fenobam.
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restoring the mGluR-LTD in Eif4ebp2 /
mice to control levels (Eif4ebp2 / vehicle vs
anisomycin;p	0.014; Fig. 1D,E). This effect
indicates that inEif4ebp2-nullmiceLTDisstill
partially dependent on de novo protein
synthesisandis similar tothenormalizationof
CA1 LTP by anisomycin or cycloheximide in
Eif4ebp2 / mice (Banko et al., 2005). Co-
treatment of hippocampal slices of Eif4ebp2-
null mice with anisomycin and JNJ16259685
abrogated the ability of each drug to rescue
mGluR-LTD when applied individually, re-
sulting inmGluR-LTD levels thatwere signif-
icantly lower than those in the group of
JNJ16259685-treated Eif4ebp2 /mice (Fig.
1B,E; Eif4ebp2 / plus JNJ16259685 vs
Eif4ebp2 /plus JNJ16259685andanisomy-
cin; t(22)	5.75,p	0.0009)andwerecompa-
rable to those of DHPG-treated Eif4ebp2 /
mice. Thus, the rescue of exaggerated LTDby
mGluR1antagonismrequires protein synthe-
sis. In contrast, the rescued mGluR-LTD by
fenobamwas insensitive to anisomycin treat-
ment (Fig. 1C,E; Eif4ebp2 / plus fenobam
vs Eif4ebp2 / plus fenobam and anisomy-
cin; t(17)	 0.06, p	 0.95). Given that both
anisomycin and fenobam reduce the ex-
aggerated mGluR-LTD in Eif4ebp2 /
mice when applied individually, the lack
of an additive effect when coadministered
suggests an occlusion of the rescue effect,
andthat fenobamactsbyreducing theprotein
synthesis-sensitive componentof the exagger-
atedmGluR-LTD inEif4ebp2 /mice.
Synaptically elicited LTD is deficient in
Eif4ebpb2/ and not rescued by group
I mGluR antagonists
Protein synthesis-dependent LTD can be induced in CA1 by using
PP-LFS of Schaffer collaterals (Huber et al., 2000). This form of
plasticity requires the activation of muscarinic acetylcholine recep-
tors, in addition to group I mGluRs (Volk et al., 2007). We deter-
mined whether the induction of PP-LFS LTD was altered in
Eif4ebp2 / mice and found that it was impaired (effect of geno-
type:F(1,48)	14.42,p	0.0009; Fig. 2A,D), suggesting adifferential
role of 4E-BP2 in chemically and synaptically induced LTD in the
hippocampus.
We then examined whether mGluR1 or mGluR5 antagonists
could rescue the impaired LTD in Eif4ebp2 /mice. JNJ16259685
or fenobam, at the doses that rescued chemically induced mGluR-
LTD, failed to normalize the deficit in LTD (effect of treatment:
F(2,48)	0.68,p	0.51; Fig. 2B,C) anddidnot affect PP-LFSLTD in
controls (Fig. 2B–D). These results are not surprising, since the role
of groupImGluRs inLTDinducedbyPP-LFS is complex, seemingly
secondary to muscarinic receptor activation in the hippocampus
(Volk et al., 2006, 2007).
JNJ16259685 and fenobam rescue social interaction and
repetitive behaviors
To investigate the effect of JNJ16259685 and fenobam on social
interaction and repetitive behaviors inEif4ebp2 /mice, we first
established the maximal tolerable dose of each antagonist that
does not impair social behavior in wild-type mice. JNJ16259285
and fenobam had no effect at the lower dose [Stranger (S) vs
Empty (E) chamber: 0.3 mg/kg JNJ16259285, p	 0.03; 3 mg/kg
fenobam, p 	 0.007; Fig. 3A] but impaired social preference at
the higher dose (S vs E: p	 1.0 for 1 and 10 mg/kg, respectively;
Fig. 3A). We verified that the antagonists reduced signaling
downstream of group I mGluRs at the lowest doses used, using
pS6 (at the Ser235/236) as the readout for mTORC1 andMAPK/
ERK activation (Thomas, 2002). Both antagonists reduced pS6 in
the hippocampus of wild-type mice 30 min after their adminis-
tration (F(4,60) 	 7.46, p 	 0.0009; vehicle vs JNJ16259285 at
0.5 h, p	 0.003; vehicle vs fenobam at 0.5 h, p	 0.012; Fig. 3B).
This reduction was transient, as levels returned to baseline 24 h
after the injection of either antagonist (vehicle vs JNJ16259285 or
fenobam at 24 h, p	 1.0; Fig. 3B). S6 phosphorylation occurs in
parallel with that of the 4E-BPs, downstream of mTOR (Gingras
et al., 1999); thus, it may not necessarily correlate with increased
translation in Eif4ebp2 / mice. Indeed, in Eif4ebp2 / mice
pS6 levels were comparable to those of wild-type mice (F(1,60)	
0.15, p	 0.70; Fig. 3B), but JNJ16259285 and fenobam failed to
significantly reduce the levels of pS6, 30 min after injection
(F(4,60)	 3.91, p	 0.007; vehicle vs JNJ16259285 or fenobam at
0.5 h, p	 1.0; Fig. 3B). One potential reason for this discrepancy
is that increased levels of network activity in baseline conditions
in Eif4ebp2-null mice (Bidinosti et al., 2010; Gkogkas et al., 2013)
couldmask the contribution ofmGluR1 and R5 on S6 phosphor-
Figure 2. Synaptically induced LTD is impaired in Eif4ebp2 / mice and unresponsive to group I mGluR antagonists. A,
PP-LFS induced a stable LTD in wild-type mice, while it was completely absent in Eif4ebp2 / mice. B, PP-LFS LTD was not
affected by incubation with JNJ16259285 in wild-type mice. Similarly, the impairment in this form of LTD in Eif4ebp2 /mice
was not changed by the mGluR1 antagonist. C, The mGluR5 antagonist fenobam did not affect the response to PP-LFS in either
wild-type or Eif4ebp2 /mice.D, fEPSP slope at 70–80min after PP-LFS onset for Eif4ebp2/ (n	 12), Eif4ebp2/ plus
JNJ16259285 (n	 7), Eif4ebp2/ plus fenobam (n	 7), Eif4ebp2 / (n	 10), Eif4ebp2 / plus JNJ16259285 (n	 8),
and Eif4ebp2 / plus fenobam (n	 12). Insets inA–C are representative traces. Calibration: 50ms and 0.5mV. ***p 0.001.
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ylation in vivo. Intriguingly, despite the
lack of a short-term effect, fenobam, but
not JNJ16259285, had a delayed influence
in mice lacking 4E-BP2, resulting in re-
duced S6 phosphorylation levels 24 h
after injection (Eif4ebp2 / vehicle vs
Eif4ebp2 / fenobam at 24 h, p 	
0.006). These results suggest that, al-
though phosphorylation of S6may reflect
group I mGluR activity in wild-type mice,
this may not necessarily be the case in
Eif4ebp2-null mice.
Next, we examined whether the group
ImGluR antagonists could improve social
interaction in Eif4ebp2 / mice. As pre-
viously reported (Gkogkas et al., 2013),
Eif4ebp2 /mice display impaired social
preference, measured either as time spent
in the chamber with the stranger mouse
(baseline: F(2,44) 	 5.42, p 	 0.008;
Eif4ebp2/ S vs E chamber, p 	 0.0009;
Eif4ebp2/ S vs Eif4ebp2 / S chamber,
p 	 0.019; Eif4ebp2 / S vs E chamber,
p	 1.0; Fig. 4A) or as the time spent sniff-
ing the enclosure of the stranger mouse
(baseline: F(1,37) 	 7.05, p 	 0.012;
Eif4ebp2/ S vs E chamber, p 	 0.0009;
Eif4ebp2/ S vs Eif4ebp2 / S chamber,
p 	 0.036; Eif4ebp2 / S vs E chamber,
p	 0.25; Fig. 4B). We then administered
JNJ16259285 or fenobam to Eif4ebp2 /
or wild-type littermates. As reported
above (Fig. 3A), neither of these drugs had
a significant effect on the social preference
exhibited by Eif4ebp2/ mice [0.5 h:
F(2,33) 	 20.76, p 	 0.0009; S vs E cham-
ber, p 	 0.045 (Fig. 4A); F(1,34) 	 36.46,
p 	 0.0009; S vs E chamber, p 	 0.0009
(Fig. 4B)]. Importantly, JNJ16259285 res-
cued the deficit in social approach of
Eif4ebp2 /mice [0.5 h: S vs E chamber,
p	 0.011 (Fig. 4A); S vs E cage, p	 0.0009
(Fig. 4B)], albeit transiently, because the
rescue was not observed 24 h after
JNJ16259285 application [24 h: F(2,33) 	
37.48, p	 0.0009; S vs E chamber, p	 1.0
(Fig. 4A); F(1,37)	 20.02, p	 0.0009; S vs
E chamber, p	 0.09 (Fig. 4B)]. Fenobam
did not affect the impaired social interac-
tion in Ei4ebp2 /mice 0.5 h after injec-
tion (S vs E chamber: p	 1.0, Fig. 4A; p	
0.2, Fig. 4B). However, Ei4ebp2 / mice
exhibited a significant improvement in
social approach 24 h after fenobam treat-
ment (S vs E chamber, p 	 0.023; Fig.
4A,B). The latter result parallels our find-
ing that fenobam caused a significant re-
duction in pS6 levels 24 h after fenobam
administration (but not at 0.5 h; Fig. 3B).
Thus, despite differences in the time
course, inhibition of either mGluR1 or
mGluR5 rescues the impaired social inter-
action caused deficient 4E-BP2.
Figure 3. Effects of mGluR1 and mGluR5 antagonists on social interaction and mTORC1 signaling in wild-type mice. A,
JNJ16259285 and fenobam impaired social preference at the higher doses (1 mg/kg for JNJ16259285 and 10 mg/kg for
fenobam), but not at lower doses (0.3 mg/kg for JNJ16259285 and 3 mg/kg for fenobam; vehicle-treated mice, n	 20; for
all other groups, n	 7. C, Center). B, At doses that did not affect the social preference, JNJ16259285 and fenobam were
effective in reducing S6 ribosomal protein phosphorylation in the hippocampus of wild-type mice but not in Eif4ebp2-null
mice. Twenty-four hours after injection, the short-term effect of JNJ16259285 and fenobam disappeared in wild-typemice,
but fenobam had a delayed effect in reducing pS6 in 4E-BP2 knock-out mice; representative Western blots are presented in
the top (asterisk indicates a residual signal of the anti-tS6 antibody when probing for GAPDH). Eif4ebp2/ plus vehicle,
n	 10; Eif4ebp2/ plus JNJ16259285 at 0.5 h, n	 12; Eif4ebp2/ plus fenobam at 0.5 h, n	 11; Eif4ebp2/ plus
JNJ16259285 at 24 h, n	 3; Eif4ebp2/ plus fenobam at 24 h, n	 3; Eif4ebp2 / plus vehicle, n	 10; Eif4ebp2 /
plus JNJ16259285 at 0.5 h, n	 5; Eif4ebp2 / plus fenobam at 0.5 h, n	 5; Eif4ebp2 / plus JNJ16259285 at 24 h,
n	 5; and Eif4ebp2 / plus fenobam at 24 h, n	 8 mice per group. N.S., Not significant. *p 0.05, **p 0.01, and
***p 0.001.
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We also investigated whether JNJ16-
259285 and fenobam could reverse the
augmented marble-burying behavior in
Eif4ebp2 / mice. In wild-type mice,
JNJ16259285 and fenobam did not affect
the number of marbles buried (genotype
drug interaction: F(2,63), p 	 0.012;
Eif4ebp2/ vehicle vs fenobam, p	 1.0; or
vehicle vs JNJ16259285, p	 0.85; Fig. 4C).
In the Eif4ebp2 / mice, the increased
number of marbles buried (Eif4ebp/ ve-
hicle vs Eif4ebp2 / vehicle, p 	 0.0009)
was reversed to control levels by treat-
ment with JNJ16259285 or fenobam
(Eif4ebp2 / JNJ16259285orEif4ebp2 /
fenobam vs Eif4ebp2 / vehicle, p 	
0.0009). Thus, the inhibition of either
mGluR1 or mGluR5 rescues the enhanced
repetitivebehaviorphenotype causedbyen-
hanced cap-dependent mRNA translation.
Discussion
Here,wedemonstrated that inEif4ebp2 /
mice, the inhibition ofmGluR1 ormGluR5
rescued exaggerated mGluR-LTD (Fig. 1),
aswell as impaired social interaction and re-
petitive marble burying (Fig. 4), while leav-
ing unaltered the impaired PP-LFS LTD
(Fig. 2). Importantly, the doses required to
rescue synaptic physiology and behavior in
Eif4ebp2-null mice had no effect in wild-
type mice (Figs. 1, 2, 3, 4). These results es-
tablish the Eif4ebp2-null mouse as a tool for
the testing ofmGluR1/mGluR5 antagonists
as candidate drugs to treat ASD and cogni-
tive impairment.
Genetic or pharmacological mGluR5
inhibition rescues autistic and cognitive
phenotypes in mouse andDrosophila FXS
models (Aschrafi et al., 2005; Chuang et
al., 2005; McBride et al., 2005; Yan et al.,
2005; Do¨len et al., 2007; Osterweil et al.,
2010; Levenga et al., 2011). mGluR5 inhi-
bition is also effective in other ASD mod-
els, including BTBR mice (Silverman et
al., 2010, 2012), which model a micr-
odeletion on the human chromosome
16p11.2 (Tian et al., 2015), and in ASD-
like alterations caused by prenatal exposure to the anticonvulsant
drug valproic acid (Mehta et al., 2011). These successful preclin-
ical studies led to the implementation of clinical trials with
mGluR5 antagonists in FXS. An early open-label clinical trial
with fenobam showed an improvement in the general anxiety
level and in prepulse inhibition, without safety concerns in FXS
(Berry-Kravis et al., 2009), but this was not followedupby further
trials (Scharf et al., 2015). Other mGluR5 antagonists (AFQ056,
Novartis; STX107, Seaside Therapeutics; RO4917523, Roche)
also had initial successes, yet more recently failed to show signif-
icant symptomatic improvement compared with placebo in
patients (Healy et al., 2011; Jacquemont et al., 2011; Gross et
al., 2012; Scharf et al., 2015). The compound AFQ056 ap-
peared to improve the behavioral outcome in FXS patients
with fully methylated alleles (and no detectable FMR1
mRNA), but not in those with partial methylation (Jacque-
mont et al., 2011), suggesting that the underlying genetic vari-
ability may be important for the responsiveness to treatment.
Our current study shows that the therapeutic effect of
mGluR5 inhibition with fenobam is also evident in a model
where cap-dependent translation initiation is augmented. Addi-
tionally, we demonstrated that mGluR1 is also a promising drug
target. In this regard, both fenobam and JNJ16259285 were
equally potent in rescuing exacerbated chemically induced
mGluR-LTD, and increased marble burying, although they dif-
fered in the time course of their beneficial effect on impaired
social interaction and on phosphorylation levels of hippocampal
S6. The reason for the delayed effect of fenobam is unclear, as
antagonists of mGluR5 (MPEP or GRN-529) have a short-term
Figure 4. Rescue of social interaction deficits and repetitive behavior by mGluR1 and mGluR5 antagonists in Eif4ebp2 /
mice.A,Wild-type or Eif4ebp2 /micewere tested after treatmentwith vehicle, JNJ16259285, or fenobam (0.5 and 24 h after).
JNJ16259285 had a short-term effect, rescuing the social approach (time spent in chamber with a stranger mouse) in
Eif4ebp2 / mice at 0.5 h after treatment, but not 24 h later. Fenobam also rescued the social preference in Eif4ebp2 /
mutant mice, but 24 h after treatment. B, The effect on social preference was corroborated by the time spent by the mice sniffing
the enclosure with the stranger mouse. JNJ16259285 and fenobam did not affect social preference in wild-type mice.
Eif4ebp2/, n	 21, of which 10 were treated with JNJ16259285 and 10 with fenobam; Eif4ebp2 /, n	 22, of which 11
were treatedwith JNJ16259285and11with fenobam.C, In themarble-burying task, the elevatednumber ofmarbles buriedby the
Eif4ebp2 /micewas reduced to control levels by JNJ16259285 and fenobam treatment. The antagonists did not affectmarble
burying in wild-type mice. Eif4ebp2/ plus vehicle, n 	 12; Eif4ebp2/ plus JNJ16259285, n 	 7; Eif4ebp2/ plus
fenobam,n	10; Eif4ebp2 /plus vehicle,n	16; Eif4ebp2 /plus JNJ16259285,n	9; and Eif4ebp2 /plus fenobam,
n	 13. N.S., Not significant. *p 0.05, **p 0.01, and ***p 0.001.
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effect on social interaction in other ASDmodels (Silverman et al.,
2010, 2012; Mehta et al., 2011).
Eif4ebp2 /mice are more sensitive, at the electrophysiolog-
ical and behavioral level, than their wild-type littermates to the
effects of mGluR1/mGluR5 antagonists. The mechanism for this
increased sensitivity is not straightforward, but may involve
MAPK/ERK signaling (Banko et al., 2006). Given that altered
hippocampal plasticity in Eif4ebp2 /mice still depends, at least
partly, on translation (Fig. 1D; Banko et al., 2005, 2006), the
ERK-MNK1/2-eIF4E pathway may be important in the thera-
peutic effect of mGluR1/mGluR5 antagonists. In addition, our
results showed that mGluR5 inhibition exerted its rescue in
Eif4ebp2 /mice via the regulation of protein synthesis, down-
stream of the initiation step. Accordingly, group I mGluRs can
regulate elongation (Park et al., 2008) and reactivation of stalled
ribosomes (Graber et al., 2013). In contrast, the rescue ofmGluR-
LTD by mGluR1 antagonist JNJ16259285 requires protein syn-
thesis activation. One potential explanation for the differential
requirement of protein synthesis by mGluR1 andmGluR5 is that
each receptormay involve different cellular substrates. For exam-
ple, mGluR1 is enriched in CA1 oriens-alveus interneurons
(Baude et al., 1993; Ran et al., 2009). Therefore, inhibition by
JNJ16259285 may preferentially affect this subpopulation of in-
terneurons and indirectly impact pyramidal cell function. In con-
trast, mGluR5 appears to be localized on the neurites of
pyramidal neurons in the hippocampus (Lo´pez-Bendito et al.,
2002) and therefore directly impact their function.
Synaptically inducedLTDwascompletely absent inEif4ebp2 /
mice, indicating that the control of cap-dependent mRNA transla-
tion through4E-BP2 is necessary for its induction. In this regard, the
absence of 4E-BP2 may result in increased levels of an endogenous
inhibitor of synaptically induced LTD, or an occlusion of induction
due to the saturation of endogenous mechanisms. Our findings in-
dicate a critical, yet distinct, involvement of 4E-BP2 regulation of
cap-dependent mRNA translation in synaptically and chemically
induced LTD.
Our results clearly indicate that enhanced signaling through
group ImGluRplays a role in the pathophysiology induced by the
absence of 4E-BP2, a key repressor of cap-dependent translation
initiation in the brain. Consequently, antagonists of mGluR1 or
mGluR5may be candidates for drugs to correct deficits in synap-
tic plasticity and behavior relevant for ASD due to dysregulated
eIF4E-dependent translation.
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